Tibet Rhodiola Pharmaceutical Holding Co. (SHA:600211)

SHA:600211 Revenue

Tibet Rhodiola Pharmaceutical Holding Co. had revenue of 723.55M CNY in the quarter ending March 31, 2026, with 1.61% growth. This brings the company's revenue in the last twelve months to 2.99B, up 6.34% year-over-year. In the year 2025, Tibet Rhodiola Pharmaceutical Holding Co. had annual revenue of 2.98B with 6.23% growth.

• Revenue (ttm): 2.99B
• Revenue Growth: +6.34%
• P/S Ratio: 4.41
• Revenue / Employee: 4.46M
• Employees: 671
• Market Cap: 13.19B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	2.98B	174.82M	6.23%
Dec 31, 2024	2.81B	-327.62M	-10.45%
Dec 31, 2023	3.13B	579.72M	22.69%
Dec 31, 2022	2.55B	416.02M	19.45%
Dec 31, 2021	2.14B	765.48M	55.75%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

May 16, 2026

Data Sources Report a data error